09:49 AM EST - BioVaxys Technology Corp : Highlights the potential for its DPX™ non-systemic immune educating platform to address the inherent limitations of lipid nanoparticles for packaging and delivering mRNA and other polynucleotides. Continued development of DPX-mRNA formulations is one of the Company's objectives, with BioVaxys pursuing collaborations with companies and academic institutions that possess pipelines of promising tumor and virus-specific polynucleotide antigens. The BioVaxys' DPX™ platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.06.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7900402145463466
